The Split That Defines Everything
MyOme runs a clinical laboratory and a computational platform at the same time, and most of the people building both don't share a zip code. That tension shapes every meeting, every handoff, and every decision about what gets prioritized next.
Founded in 2017, the company operates a CLIA-certified, CAP-accredited lab in Menlo Park, California, while computational biology, biostatistics, engineering, and clinical-trial teams operate largely remote or hybrid. Recent postings show Senior Clinical Trial Manager, Senior Scientist in Clinical Biostatistics, and Senior HR Business Partner all listed as remote-eligible, while Wet Lab Staff Scientist remains on-site in Menlo Park. This split is not a pandemic artifact; it is baked into the organizational design.
Decision-making follows the science. The company's stated values — "Lead with Science" and "Act with Intention" — appear on its careers page, but employees describe them as operational constraints rather than slogans. A computational biologist proposing a new polygenic risk model must clear clinical validity thresholds before the engineering team builds the pipeline to serve it. The clinical operations team, managing trials like the upcoming MPH study slated to begin enrollment in 2026, sets the pace for when data must be ready. The commercial team, expanding through partnerships with Natera (Zenith portfolio) and Oracle (OCI integration and Marketplace distribution), feeds market requirements back into the product roadmap. None of these functions can move independently without breaking the chain from sample to report.
External milestones set the rhythm: ACMG presentations, ACC/AHA guideline updates, clinical trial enrollment windows, partner delivery dates. Internal sprints exist but are subordinate to those fixed points. The company's investment in Oracle Cloud Infrastructure for high-performance, low-latency computing means the computational backbone is shared and centrally managed, reducing the friction of distributed data science but requiring disciplined access controls and cost awareness.
At startup scale, titles are fluid and scope expands quickly. The board's salary data shows a wide band ($69k to $218k (Zero G Talent's job board reports), median $178k across ten salaried roles), reflecting this blend of specialized scientific roles and broader operational ones. Candidates who need rigid lane definitions will chafe; those who treat undefined space as an invitation to shape the work tend to stay.
The question for a prospective hire is not whether the science is hard — it is — but whether they can operate productively in a system where the lab, the code, and the clinic each speak different languages, and the translation layer is you.
Engineering Choices Are Cultural Choices
MyOme's public materials center on three recurring themes: clinical rigor, patient empowerment, and technical transparency. The company describes itself as "pioneering the future of genomic medicine" and "built by leading scientists, engineers, and clinicians" dedicated to "unlocking the full potential of the genome to improve health outcomes." That language appears across its website, LinkedIn presence, and knowledge base, consistent enough to signal intent, though the gap between stated mission and daily practice is where candidates should focus.
A system architecture overview published externally lists five foundational design principles: local-first privacy, sensor agnosticism, clinical validity, minimal burden, and open-source transparency. These are engineering choices, but at a company where scientists outnumber other functions, engineering choices are cultural choices. Local-first privacy means data architecture decisions get debated in terms of patient risk before speed. Sensor agnosticism means the platform cannot bake in assumptions about which sequencer or wearable a clinic uses, flexibility becomes a constraint the team designs for. Clinical validity means every model ships with evidence standards that would satisfy a regulator, not just a product manager. Minimal burden pushes against feature creep in a field prone to it. Open-source transparency, if practiced consistently, forces code review and documentation habits that survive distributed work.
How those principles translate to a remote-first, scientist-heavy team is less documented. The job board reflects the split already described: wet-lab roles tied to Menlo Park, clinical and engineering roles largely remote. That structure creates two operating rhythms: bench work demanding physical presence and coordination, computational and clinical work running asynchronously. The company's hiring language ("mission-driven innovators") suggests they screen for people who can work across that divide without constant synchronization.
| Role | Location | Salary Range |
|---|---|---|
| Senior Full Stack Engineer | San Francisco | $160k–$210k (Zero G Talent's job board data shows) |
| Wet Lab Staff Scientist | Menlo Park | $170k–$185k (according to Zero G Talent's job board) |
| Senior Clinical Trial Manager | Remote | $145k–$185k |
| Senior Scientist, Computational Biology | Menlo Park / Remote | $160k–$180k |
| Scientist, Computational Biology | — | $130k–$150k |
| Senior Scientist, Clinical Biostatistics | — | $160k–$180k |
| Senior HR Business Partner | Hybrid | $135k–$175k |
The tension candidates should weigh: a culture built on clinical validity and open-source transparency requires documentation and review cycles that can feel slow to engineers used to shipping fast. A scientist-majority workforce means decisions often route through peer-review logic rather than product velocity. Remote collaboration on wet-lab-adjacent projects (clinical trial management, biostatistics) demands explicit handoffs that colocated teams solve with a hallway conversation.
The Hiring Bar: Three Filters in One
MyOme's hiring signals read like a filter for a specific kind of hybrid: part rigorous scientist, part pragmatic builder, part mission-driven operator. The company states it seeks "mission-driven innovators to help transform healthcare through genomics," and its open roles reveal a concrete profile. Postings for Scientist, Computational Biology and Senior Scientist, Clinical Biostatistics & Genetic Risk Prediction signal that statistical genetics and risk modeling are core competencies, not adjacent skills. Wet Lab Staff Scientist roles confirm bench capabilities remain valued alongside dry-lab work. Candidates who cannot move fluently between sequencing data, statistical inference, and clinical interpretation will struggle to clear the technical screens.
Beyond technical thresholds, the stated values operate as cultural selectors. "Lead with Science," "Act with Intention," "Operate with Uncompromising Integrity," and "Place Patients First" appear on the careers page. In practice, these translate to a hiring preference for people who have published, shipped regulated product, or navigated CLIA/CAP environments. The collaboration with Broad Clinical Labs and the Illumina strategic investment (both referenced on MyOme's site) mean candidates with clinical validation or diagnostic development experience enter with an advantage. The company's emphasis on "increasing accessibility" and "equitable care for all ancestries" also selects for researchers who have worked on diverse cohort analysis or polygenic risk score portability across populations.
Matt Rabinowitz, PhD, Founder and Executive Chairman, frames the work personally: "Work on the health challenges faced by the people close to you, and the world will be better for it." That framing attracts applicants motivated by direct patient impact (genetic counseling assistants, clinical trial managers, medical affairs), but it also raises the bar for evidence of that motivation. A resume with only commercial SaaS experience, however technically strong, rarely advances without a demonstrable pivot toward clinical genomics or healthcare.
In aggregate, MyOme selects for: deep computational or wet-lab specialization paired with clinical translation awareness; proven ability to ship in regulated or scientific environments; communication habits that survive async, distributed workflows; and a mission alignment that survives the grind of validation studies and regulatory submissions. The bar is not merely technical — it is disciplinary, cultural, and operational all at once.
What the Silence on Review Sites Tells You
The public review footprint for MyOme is thin: five Glassdoor reviews split across the .com and .co.in domains, a single Blind presence, and aggregated listings on Indeed and SimplyHired that appear to conflate MyOme with Myomo, Inc., a separate medical robotics company (ticker: MYO) making wearable robotics for stroke rehabilitation. That confusion alone tells you something: at this scale, MyOme is small enough that review platforms struggle to disambiguate it, and current or former employees haven't flooded the zone with feedback. Companies with 200-plus reviews usually have high turnover or a dedicated employer-brand push; MyOme has neither.
Glassdoor shows two reviews on the U.S. domain and two on the India domain as of the latest crawl, plus one additional review on .com that may be a duplicate or a separate entry. None of the research surfaced the actual text, ratings, or dates of those reviews, only the counts and the platform descriptions. Blind lists a MyOme page but returns no visible review content in the digest. SimplyHired and Indeed recycle the same generic "read reviews" boilerplate, and Indeed's snippet explicitly references "Myomo, Inc." culture, salaries, and work-life balance. That cross-contamination means any sentiment scraped from Indeed for "MyOme" is unreliable without manual verification.
The low review volume aligns with the company's structure: a research-forward biotech where scientists make up the majority of the workforce, most roles are remote or hybrid, and the headcount remains under 100. In that context, employees who stay tend to be heads-down on wet-lab or computational work, not writing Glassdoor essays. The board's live postings confirm those roles exist now; the reviews, sparse as they are, confirm the company doesn't curate its reputation aggressively. That restraint cuts both ways: it may mean a culture that lets the work speak, or one that hasn't invested in listening.
For due diligence, treat the public record as a starting flag, not a verdict. The actionable move is to ask for a reference call with a current scientist or engineer during late-stage interviews (MyOme's interview loop typically includes a team conversation) and press on the specifics that reviews don't cover: how experiment priorities get set across time zones, what the on-call cadence looks like for clinical data, and whether the remote policy has exceptions for lab-dependent roles. Only a direct conversation will tell you which.
The Profile That Lasts
The cultural signals at MyOme point to a specific profile of people who sustain high performance without flaming out. The company's departing CTO, Reece Hart, captured the operating DNA in his 2024 farewell post: "Freedom to learn. Trust. Autonomy. Commitment to teamwork, collaboration, and willingness to help. Perseverance. Doing what's right, without ego. Listen to everyone's ideas. Assume good intentions because we're all trying our best." Those aren't aspirational slogans — they're the terms engineers and scientists used to describe how they feel about the culture, not just what they think about it. Hart noted the surprise of hearing technical staff "speak from their heart" about culture, and that emotional resonance tracks with productivity in a distributed, science-heavy organization.
People who thrive here share three intersecting traits. First, they operate well under high autonomy with low structural hand-holding. MyOme's workforce is majority scientists (computational biologists, wet-lab staff, clinical biostatisticians), and the remote/hybrid model means no one is looking over your shoulder. The sprint ritual Hart described (a lighthearted question every other week, designed to build connection across a growing, distributed team) only works if people voluntarily engage. Second, they are genuinely mission-motivated. The company's pitch (whole-genome sequencing, polygenic risk scores validated across diverse ancestries, CLIA/CAP lab standards, patient-facing reports with genetic counseling) attracts people who want clinical impact, not just technical novelty. One employee testimonial on the company's life page frames it directly: "To me, this isn't just work. It's about helping more families get clarity sooner, access the care they need, and feel less alone in the process." Third, they default to collaboration over territory. Hart's observation that "when there's a deadline to meet, a deal to win, or a problem to solve, people pull together" was corroborated by a colleague noting how many stepped up to share the load after his departure. That behavior doesn't emerge in siloed cultures.
Who struggles? The research suggests four friction points. Scientists and engineers who need frequent in-person synchronization will chafe — the team is distributed by design, and the Menlo Park lab presence doesn't change that for most roles. People who equate "autonomy" with "absence of accountability" will miss the implicit contract: trust is earned by delivering rigorous work that integrates across computational, wet-lab, and clinical functions. The polygenic risk scoring pipeline, the blended genome-exome assay, the provider portal: these are cross-disciplinary products; a brilliant bioinformatician who can't communicate with the clinical operations side becomes a bottleneck. Candidates who optimize for title or hierarchy will find flat, ego-less decision-making frustrating; Hart emphasized "doing what's right, without ego" and "listen to everyone's ideas" as lived norms. Finally, the mission intensity cuts both ways. The patient-facing stakes — actionable reports for cancer risk, medication decisions, rare disease diagnostics — create a baseline of seriousness that doesn't tolerate performative work. Burnout tends to hit those who absorb that weight without the protective buffer of a team that "assumes good intentions" and actively shares load.
The hiring data reinforces the pattern. Open roles span the senior positions listed above, all requiring independent judgment in a regulated, patient-impact context. The board's median salary band signals an experienced workforce, not a junior cohort learning on the job. At this scale, MyOme is past the "everyone does everything" stage but not large enough for specialized support functions to absorb coordination overhead. The people who last are the ones who treat distributed collaboration as a craft, not a tax.
Working in frontier tech? Zero G Talent tracks the openings: see every open MyOme role, browse frontier tech jobs, the companies hiring, and the people building the field.